Navigation Links
MISTY OX® Variable Flow Nebulizer

ProductsMISTY OX® Variable Flow Nebulizer
Company Vital Signs, Inc.
Item MISTY OX® Variable Flow Nebulizer
Features 
  • Can operate cool or heated with optional TurboHeaterTM
  • Threads on any standard 38mm diameter hospital pour bottle
  • Exclusive Venturi and baffle reduces rainout
  • For use in facilities that only have a single O2 gas source available
  • To provide medium to high flows with superior hydration to the patient
  • For use in the Emergency Room as well as other treatment areas
  • Replaces other air entrainment nebulizers that provide only limited FIO2 and limited flow
  • 24 per case
Description Benefits:
  • One device provides both low FIO2 and high FIO2 therapy from a single gas source
  • Reduce supply chain costs by decreasing the number of SKUs dedicated to nebulizers
  • Eliminate the expense and inconvenience of double or wye set ups
  • Replace complicated venturi mask aerosol delivery systems
Info Vital Signs, Inc.
Customer Service: (800) 932-0760
Web site: http://home.vital-signs.com/home/homepage.asp

Related medicine products :

1. MISTY OX® Hi-Fi Nebulizer
2. MISTY OX® Gas Injection Nebulizer (GIN)
3. OCUFLOX® 1 mL
4. OCUFLOX® 5 mL
5. BOTOX® Cosmetic Botulinum Toxin Type A
6. Cauterette I, Variable low temperature handle (requires disposable tips)
7. Variable Speed Pump 120 V
8. Masterflex Economy Drive Variable Speed Peristaltic Pump (CE 230V - US 115V)
9. Variable Volume Pipette H1000
10. Variable Volume Pipette H200
11. Variable Volume Pipette H20
Breaking Medicine News(10 mins):Health News:The Flag Company, Inc.'s Recently Released “Feel Good” Light Lenses Grows Into Its Own Website 2Health News:The Flag Company, Inc.'s Recently Released “Feel Good” Light Lenses Grows Into Its Own Website 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 2Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 4Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 5Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 6Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 7Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 8Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 9Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 10Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 11Health News:Patriot Scientific Corporation Announces New Director 2Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 2Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 3Health News:Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure 2Health News:Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure 3
Other Medicine News:Health News:Agito Networks Wins the 2008 VON Magazine Innovator Award for Enterprise Mobility 2Health News:Agito Networks Wins the 2008 VON Magazine Innovator Award for Enterprise Mobility 3Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 2Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 3Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 4Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 2Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 3Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 4Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 5Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 6Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 7Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 2Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 3Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 4Health News:Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention 2Health News:Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention 3
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Eliminate the Blues with Color Therapy 54599 1Eliminate the Blues with Color Therapy 54599 2Eliminate the Blues with Color Therapy 54599 3New biofactories produce rare healing substances in the endangered Devils claw plant 54597 1New biofactories produce rare healing substances in the endangered Devils claw plant 54597 2New biofactories produce rare healing substances in the endangered Devils claw plant 54597 3Heroes of Chemistry for saving teeth clean water new high blood pressure drug 54594 1Heroes of Chemistry for saving teeth clean water new high blood pressure drug 54594 2Heroes of Chemistry for saving teeth clean water new high blood pressure drug 54594 3Heroes of Chemistry for saving teeth clean water new high blood pressure drug 54594 4